Navigation Links
OHSU research suggests compound administered during some bone marrow transplants elevates risks
Date:9/21/2010

PORTLAND, Ore - Research conducted at Oregon Health & Science University's Vaccine and Gene Therapy Institute may spur debate about the risks associated with administering a specific compound in some forms of bone-marrow transplantation. The research is published in the current edition of Cell Host and Microbe.

The VGTI research team, led by institute director Jay Nelson, Ph.D., studies human cytomegalovirus, a virus that may infect up to 80 percent of the American population. The exact percentage of infected citizens is unknown due to the fact that the virus causes minor symptoms or no symptoms at all in most healthy people. However, the virus can pose a significant risk in people whose immune system has been compromised, such as those infected with HIV, or patients who have had their immune systems suppressed through chemotherapy or with anti-rejection medications during transplantation.

During this specific research project, Nelson, along with M. Shane Smith, Ph.D., a postdoctoral fellow in Nelson's lab and other colleagues focused on the impact of granulocyte-colony stimulating factor, or G-CSF, on the virus. G-CSF is a hormone frequently administered to bone marrow transplant donors to stimulate stem cell growth and localization of blood prior to harvesting blood-borne stem cells.

While G-CSF-induced stem cell localization to the blood does provide a more comfortable means of stem cell donation compared to the previous method of harvesting cells directly from the bone marrow, previous studies have suggested that bone marrow transplantation performed with blood-borne stem cells places recipients at double the risk for HCMV and chronic graft-versus host disease.

The VGTI research team uncovered the mechanism behind this associated risk. Using a mouse model of the disease, the scientists determined that G-CSF causes HCMV, which is in a dormant or latent state in the bone marrow, to reactivate in stem cells, thereby placing stem cell recipients at elevated risk for HCMV transmission and disease.

"Because bone marrow recipients' immune systems are so significantly compromised, this risk is very significant," said Nelson. "We believe this research will generate discussion about the proper applications for G-CSF which continues to provide benefits but the risk associated must also be factored into patient care."


'/>"/>

Contact: Jim Newman
newmanj@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Embedded Mobile & M2M Device revenues to Rise to Almost $19 Billion Globally by 2014, Says Juniper Research
2. 2010 HSR Impact Award recognizes surgical safety research
3. MSU launches first anti-counterfeiting research program
4. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
5. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
6. Researchers discover new way to kill pediatric brain tumors
7. Family Research Council: Planned Parenthood Report Oversexualizes Ten-Year-Olds, Undermines Parental Authority
8. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
9. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
10. International Diabetes Federation awards $2 million to 9 global diabetes research projects
11. Gladstones Robert Mahley to receive Research!America advocacy award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... is pleased to be invited to the Siemens Healthineers annual customer education symposium, ... The event will take place from March 27 - 31, 2017 at the ...
(Date:3/28/2017)... ... 2017 , ... Medforce Technologies, Inc., a leading provider of ... joined the National Association for Home Care and Hospice (NAHC), the largest and ... Americans of all ages and the caregiver who provide them with in-home health ...
(Date:3/28/2017)... ... 28, 2017 , ... WHO: , Dr. Paul Thomas; Dr. Brian Hooker; Dr. ... and PhD scientists will speak to the press on behalf of over 200 doctors, ... independent vaccine safety commission. , WHERE: , Zenger Room, National Press Club, 529 ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... relocated its corporate headquarters to a new, more expansive office space in order ... 2016, Qualidigm purchased a distressed office building in Wethersfield, Conn. located at 936 ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & ... money to for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and ... of $70 billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... "Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology and Market Forecast-2023" ... of the Chemotherapy Induced Neutropenia for the seven major markets i.e., ... ( France , Germany , ... Japan , as well as rest of ... The Report covers the therapeutics market revenue, treatment practice ...
(Date:3/28/2017)... -- "US Cancer Generics Market Outlook 2022" report gives ... analysis related to the emergence and integration of ... US. The report analyzes various clinical and non-clinical ... drugs in recent years. The introduction of generics ... for various stake holders involved US cancer drug ...
(Date:3/28/2017)... TORONTO , March 28, 2017 /PRNewswire/ - ... service medical device development firm, announced today that it ... Toronto -based medical device industrial design and productization ... companies throughout North America with ... device talent spanning the design, engineering, regulatory, and manufacturing ...
Breaking Medicine Technology: